Table 1 Baseline characteristics of patients suspected for FH
Characteristics | Patients suspected for FH | |||
|---|---|---|---|---|
Total | Male | Female | P | |
N | 61 | 22 | 39 | 0.001 |
Age - yo (mean±SD) | 48.4 ± 12.5 | 46.1 ± 1 | 49.7 ±1 | 0.4 |
Smoker n (%) | 18 (29.5%) | 12 (54.5%) | 6 (15.4%) | 0.001* |
High blood pressure n (%) | 31 (50.8%) | 13 (59.1%) | 18 (46.2%) | 0.3 |
CHD history n (%) | 28 (21.3%) | 6 (27.3%) | 22 (17.9%) | 0.5 |
PAD history n (%) | 10 (14.8%) | 3 (13.6%) | 7 (15.4%) | 0.5 |
CHD+PAD history n (%) | 11 (23%) | 5 (22.7%) | 6 (23.1%) | 0.5 |
Obesity n (%) | 36.1% | 8 (36.4%) | 14 (35.9%) | 0.9 |
Type 2 diabetes n (%) | 8 (13.1%) | 4 (18.2%) | 4 (10.3%) | 0.4 |
Physical inactivity n (%) | 30 (49.2%) | 14 (63.6%) | 16 (41%) | 0.09 |
TC mg/dL (median±IQR) | 315 ± 56 | 313.5 ± 41 | 315 ±60 | 0.7 |
LDL-C mg/dL (mean±SD) | 254.2 ± 53 | 257 ±63 | 252.5± 47 | 0.8 |
HDL-C mg/dL (median± QR) | 45.8 ±18 | 44 ±19 | 46 ±18 | 0.6 |
TG mg/dL (mean±SD) | 174.4 ± 92 | 163.7± 90 | 180.5± 94 | 0.6 |
Uric acid mg/dL (mean±SD) | 5.79 ± 1.22 | 6.2 ±1.1 | 5.5 ±1.2 | 0.02* |
hsCRP mg/L (mean±SD) | 5.85 ± 2.29 | 6.3 ±2.5 | 5.9± 2 | 0.5 |
ECG changes n (%) | 25 (41%) | 11 (50) | 14 (35.9) | 0.3 |
LV wall motion abnormalities n (%) | 25 (41%) | 11 (50) | 14 (35.9) | 0.1 |
ABI (mean±SD) | 0.96±0.93 | 0.84±0.09 | 1.01±1.4 | 0.8 |
cIMT mm (mean±SD) | 0.95±0.33 | 1.02±0.34 | 0.9±0.32 | 0.2 |
Lipid-Lowering Agents | 0.3 | |||
Statin n (%) | 22 (36.1%) | 7(39.8%) | 15(38.5%) | |
Statin + ezetimibe n (%) | 18 (29.5%) | 11 (50%) | 7 (17.9%) | |
Statin + fenofibrate n (%) | 8 (13.1%) | 3 (13.6%) | 5 (12.8%) | |
Statin + fenofibrate + ezetimibe n (%) | 13 (21.3%) | 1 (4.5%) | 12 (30.8%) | |
Adverse effects n (%) | 3% | 1% | 2% | |